The global drug repurposing market was valued at $34.79 billion in 2025 and is projected to reach $50.91 billion by 2035, growing at a 3.93% CAGR from 2026 to 2035, according to SNS Insider. Repurposing uses existing medicines and established safety, pharmacological, manufacturing and clinical-trial information to reduce the time and cost of developing treatments for new indications. Demand is being supported by rare diseases, unmet medical needs, emerging infections and rising pharmaceutical research costs. Artificial intelligence and machine learning are helping analyze biological, clinical, molecular, genomic, proteomic and real-world evidence datasets to identify drug-disease relationships. North America held about 39% of the market in 2025, while Asia Pacific is projected to be the fastest-growing region at approximately 5.02% CAGR. Small molecules, oncology treatments, oral administration and pharmaceutical and biopharmaceutical companies were the leading segments by share. Biologics, neurology and central nervous system disorders, intravenous delivery and contract research organizations are expected to grow fastest within their respective categories. The report identifies computational drug discovery and collaboration between pharmaceutical companies and AI technology firms as opportunities, while limited intellectual-property protection remains a barrier. It also cites activity by Every Cure, REMEDi4ALL and Recursion Pharmaceuticals, alongside major pharmaceutical companies and other specialized repurposing firms.